Xeltis
About Xeltis
A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for which clinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission.
Company Metrics
- Employees: 11-50
- Monthly Visits: 10278
- Tech Stack: 12 active products
Financial Information
- Estimated Revenue: $1M to $10M
- Total Funding: 115500000 EUR
- Last Funding: 15000000 EUR (Series D)
- Funding Status: Late Stage Venture
Technology Stack
Xeltis actively uses 12 products in their tech stack.
Market Presence
Industries: Health Care, Medical Device, Therapeutics
Headquarters: Eindhoven, Noord-Brabant, The Netherlands
Leadership
- Eliane Schutte - CEO LinkedIn
Employees
- Patrizio Parpinel - Chief Operating Officer (LinkedIn)
- Paulo Neves - Chief Medical Officer (LinkedIn)